Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Umbilical Cord Bilirubin Predicts Neonatal Jaundice

By LabMedica International staff writers
Posted on 17 Oct 2017
Hyperbilirubinemia is one of the commonest causes of admission to hospital in the neonatal period amongst term babies in all settings. Prevention of serious complications depends on effective early treatment, but clinically significant jaundice may not develop until one or more days after delivery.

Identification of biomarkers that could be measured within a few hours following birth, which robustly predict incident jaundice, would represent a significant advance. Estimation of umbilical cord blood bilirubin (UCB) at delivery is practicable, cheap and non-invasive. It could be easily integrated with the current trend towards routine umbilical cord blood biochemical evaluation practiced in many centers.

Neonatal specialists at Homerton University Hospital (London, UK) carried out a retrospective analysis of hospital biochemistry records identified term deliveries with recorded arterial UCB (aUCB). Infant medical records were reviewed to identify those who developed neonatal hyperbilirubinemia requiring treatment according to UK NICE guidelines, with/without a positive direct antiglobulin test (DAT). Over the 9-month period, there were 4,069 inborn deliveries, on who umbilical cord blood analysis had been performed on 2,128 (52.2%). The neonatal unit is equipped with a GEM 4000 whole blood analyzer, which automatically provides total bilirubin estimation on samples.

Of 1,411 term deliveries with a clearly recorded aUCB, 30 infants developed clinically significant jaundice (2.7%), of whom eight were DAT + ve (0.6%) mostly due to ABO incompatibility. aUCB strongly predicted the development of DAT + ve jaundice, as well as all-cause jaundice. However, this effect was critically dependent on maternal blood group. Amongst infants at risk of ABO incompatibility (maternal blood groups O+ve/O-ve, 39.7%) the predictive value of aUCB for all cause jaundice was strengthened. Amongst those not at risk (defined maternal blood group not O+ve/O-ve, 51.0%) it disappeared completely. A cutoff of 35 μmol/L for mothers with blood group O+ve/O-ve increased the pre-test probability for all-cause jaundice of 4% to a post-test probability of 30%.

The authors concluded that for infants of mothers with blood group O, aUCB predicts development of neonatal jaundice. There was no evident utility for infants of mothers with other blood groups. Estimation of aUCB should be considered as a strategy for early identification of those at risk of neonatal hemolytic jaundice. The study was published on September 20, 2017, in the journal BMC Pediatrics.

Related Links:
Homerton University Hospital


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Respiratory QC Panel
Assayed Respiratory Control Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.